Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1563

Sort by

Sort Order Select

Journal Articles

Type I interferon is induced by hemolysis and drives antibody-mediated erythrophagocytosis in sickle cell disease

Yunfeng Liu, Mouli Pal, Weili Bao, Patricia A. Shi, Cheryl A. Lobo, Xiuli An, Deepa Manwani, Hui Zhong, Karina Yazdanbakhsh

Blood (2021) 138 (13): 1162–1171.

https://doi.org/10.1182/blood.2021011629

Published: 2021

Includes: Supplemental data

Journal Articles

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria

Gloria F. Gerber, Xuan Yuan, Jia Yu, Benjamin A. Y. Cher, Evan M. Braunstein, Shruti Chaturvedi, Robert A. Brodsky

Blood (2021) 137 (26): 3670–3673.

https://doi.org/10.1182/blood.2021011548

Published: 2021

Includes: Supplemental data

Journal Articles

Profound intravascular hemolysis due to clostridial sepsis in an infant with necrotizing enterocolitis

Rahela Aziz-Bose, Alan B. Cantor

Blood (2021) 137 (16): 2273.

https://doi.org/10.1182/blood.2021011159

Published: 2021

Journal Articles

How I treat cold agglutinin disease

Sigbjørn Berentsen

Blood (2021) 137 (10): 1295–1303.

https://doi.org/10.1182/blood.2019003809

Published: 2021

Journal Articles

How I treat paroxysmal nocturnal hemoglobinuria

Robert A. Brodsky

Blood (2021) 137 (10): 1304–1309.

https://doi.org/10.1182/blood.2019003812

Published: 2021

Journal Articles

Management of pyruvate kinase deficiency in children and adults

Rachael F. Grace, Wilma Barcellini

Blood (2020) 136 (11): 1241–1249.

https://doi.org/10.1182/blood.2019000945

Published: 2020

Journal Articles

Vasomotor hyperresponsiveness in SCD

Valentine Brousse, Philippe Connes

Blood (2020) 136 (10): 1120–1121.

https://doi.org/10.1182/blood.2020007070

Published: 2020

Journal Articles

Heme induces rapid endothelial barrier dysfunction via the MKK3/p38MAPK axis

Joel James, Anup Srivastava, Mathews Valuparampil Varghese, Cody A. Eccles, Marina Zemskova, Olga Rafikova, Ruslan Rafikov

Blood (2020) 136 (6): 749–754.

https://doi.org/10.1182/blood.2019003986

Published: 2020

Includes: Supplemental data

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Erica B. Esrick, MD, Maureen Achebe, MD MPH, Myriam Armant, PhD, Pablo Bartolucci, MD PhD, Marioara Felicia Ciuculescu, MD, Heather Daley, Colleen Dansereau, MSN, RN, CPN, Giuseppe Di Caprio, PhD, Bronner Goncalves, MD PhD, Nicolas Hebert, Matthew M Heeney, MD, John M. Higgins, MD PhD, Leslie E. Lehmann, MD, John P Manis, MD, Olivier Negre, PhD, Sarah Nikiforow, MD PhD, Ethan Schonbrun, PhD, David K. Wood, PhD, David A. Williams, MD

Blood (2019) 134 (Supplement_2): LBA-5.

https://doi.org/10.1182/blood-2019-132745

Published: 2019

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Stella Lin, Xiaoyu Jiang, Caroline Reuter, William Hobbs, Sigbjørn Berentsen

Blood (2019) 134 (Supplement_2): LBA-2.

https://doi.org/10.1182/blood-2019-132490

Published: 2019

Journal Articles

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Iara Baldim Rabelo Gomes, MD PhD, Vinicius Campos de Molla, MD, Andre Domingues Pereira, MD, Roberta Shcolnik Szor, MD, Martha Mariana Arruda, MD PhD, Maria Stella Figueiredo, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2222.

https://doi.org/10.1182/blood-2019-132023

Published: 2019

Journal Articles

Mn Porphyrin-Based Redox Active Drugs Improve Anemia and Reduce Organ Damage in a Murine Model of Sickle Cell Disease

Madhan Thamilarasan, PhD, Rodolfo Estupinan, Rahima Zennadi, PhD

Blood (2019) 134 (Supplement_1): 2255.

https://doi.org/10.1182/blood-2019-131140

Published: 2019

Journal Articles

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study

Kenneth I. Ataga, MD, Abdullah Kutlar, MD, Laurie DeBonnett, MD, Jeremie Lincy, Julie Kanter, MD

Blood (2019) 134 (Supplement_1): 2289.

https://doi.org/10.1182/blood-2019-125868

Published: 2019

Journal Articles

Iron Restriction Improves Markers of Disease Severity in the Townes Mouse Model of Sickle Cell Anemia

Nermi Parrow, PhD, Pierre-Christian Violet, PhD, Nisha George, PhD, Faris Ali, Shivam Bhanvadia, Mark Levine, MD, Robert E Fleming, MD

Blood (2019) 134 (Supplement_1): 2261.

https://doi.org/10.1182/blood-2019-130732

Published: 2019

Journal Articles

Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Satheesh Chonat, MD, Earl Fields, Hannah Baratz, Amanda Watt, Mira Pochron, PhD, Sandy Dixon, Margaret Tonda, PharmD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Clark Brown, MD PhD, David R. Archer, PhD

Blood (2019) 134 (Supplement_1): 2281.

https://doi.org/10.1182/blood-2019-129351

Published: 2019

Journal Articles

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Elliott P. Vichinsky, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD, Margaret Tonda, PharmD, Barbara Tong, PhD, Irene Agodoa, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Kenneth I. Ataga, MD

Blood (2019) 134 (Supplement_1): 2313.

https://doi.org/10.1182/blood-2019-129026

Published: 2019

Journal Articles

Downregulation of Cytoskeletal Protein Kazrin in Lung Endothelial Cells of Preclinical Sickle Cell Disease Mouse Model - Essential Role of Endothelial Barrier Function

Umapathy N Siddaramappa, PhD, Niren Patel, MBBS, Betty S. Pace, MD, Abdullah Kutlar, MD

Blood (2019) 134 (Supplement_1): 2258.

https://doi.org/10.1182/blood-2019-130924

Published: 2019

Journal Articles

Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Antonio M. Risitano, MD PhD, Jong Wook Lee, MD PhD, Rosario Notaro, MD, Robert A. Brodsky, MD, Austin Kulasekararaj, MBBS MDMRCP FRCPath, Jaroslaw P. Maciejewski, MD PhD, Mingjun Huang, PhD, Michael Geffner, MD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 2226.

https://doi.org/10.1182/blood-2019-124837

Published: 2019

Journal Articles

Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Early Death in Sickle Cell Disease

Annelies J. Van Vuren, MD, Laurel Mendelsohn, BS, Richard van Wijk, PhD, Caterina P. Minniti, MD, John Baird, MD, Gregory J Kato, MD, Eduard J. van Beers, MD PhD

Blood (2019) 134 (Supplement_1): 2274.

https://doi.org/10.1182/blood-2019-124048

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Type I interferon is induced by hemolysis and drives antibody-mediated erythrophagocytosis in sickle cell disease

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria

Profound intravascular hemolysis due to clostridial sepsis in an infant with necrotizing enterocolitis

How I treat cold agglutinin disease

How I treat paroxysmal nocturnal hemoglobinuria

Management of pyruvate kinase deficiency in children and adults

Vasomotor hyperresponsiveness in SCD

Heme induces rapid endothelial barrier dysfunction via the MKK3/p38MAPK axis

A complementary new drug for PNH

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Mn Porphyrin-Based Redox Active Drugs Improve Anemia and Reduce Organ Damage in a Murine Model of Sickle Cell Disease

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study

Iron Restriction Improves Markers of Disease Severity in the Townes Mouse Model of Sickle Cell Anemia

Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Downregulation of Cytoskeletal Protein Kazrin in Lung Endothelial Cells of Preclinical Sickle Cell Disease Mouse Model - Essential Role of Endothelial Barrier Function

Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Early Death in Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only